Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavras, PD, Wang, Y, Gandhi, A, Lontos, K, Delgoffe, GM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572744/
https://www.ncbi.nlm.nih.gov/pubmed/31354288
http://dx.doi.org/10.2147/OTT.S177844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572744/
https://www.ncbi.nlm.nih.gov/pubmed/31354288
http://dx.doi.org/10.2147/OTT.S177844

Ejemplares similares